Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

Vivek Subbiah; Ulrik Lassen; Eduard Gasal; Paul Burgess; Zev A. Wainberg

doi:10.1016/S1470-2045(20)30625-2

Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer – Authors' reply

Vivek Subbiah, Ulrik Lassen, Eduard Gasal, Paul Burgess, Zev A. Wainberg

Investigational Cancer Therapeutics

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	e516
Journal	The lancet oncology
Volume	21
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(20)30625-2
State	Published - Nov 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(20)30625-2

Cite this

@article{cf3d44892eb54599bd9b1cf4abfe2cbb,

title = "Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply",

author = "Vivek Subbiah and Ulrik Lassen and Eduard Gasal and Paul Burgess and Wainberg, {Zev A.}",

year = "2020",

month = nov,

doi = "10.1016/S1470-2045(20)30625-2",

language = "English (US)",

volume = "21",

pages = "e516",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "11",

}

TY - JOUR

T1 - Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

AU - Subbiah, Vivek

AU - Lassen, Ulrik

AU - Gasal, Eduard

AU - Burgess, Paul

AU - Wainberg, Zev A.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85094843185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094843185&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(20)30625-2

DO - 10.1016/S1470-2045(20)30625-2

M3 - Letter

C2 - 33152307

AN - SCOPUS:85094843185

SN - 1470-2045

VL - 21

SP - e516

JO - The lancet oncology

JF - The lancet oncology

IS - 11

ER -

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer – Authors' reply